TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01815476

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy Positioning Intervention
Description: All participants will receive an adjuvant XRT dose to the breast of 50Gy in 25 fractions using an IMRT technique. In both arms, boost to the surgical bed using a mini-tangent technique will be delivered at the treating oncologist's discretion. Acceptable boost doses are 1600cGy/8 fractions, 1000cGy/5 fractions or 1325cGy/25 fractions as a simulatenous integrated boost. Participants randomized to the supine arm will be positioned supine on an angled breast board, with the ipsilateral arm abducted over her head. Participants randomized to the prone arm will be positioned prone on a prone breast board with both arms immobilized above the participant's head. The us of a cushion-like VaclocTM device is permitted at the treating physician's discretion. Radiation beams will be shaped to encompass the breast volume requiring treatment in both arms.

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy Positioning Intervention
Description: All participants will receive an adjuvant XRT dose to the breast of 50Gy in 25 fractions using an IMRT technique. In both arms, boost to the surgical bed using a mini-tangent technique will be delivered at the treating oncologist's discretion. Acceptable boost doses are 1600cGy/8 fractions, 1000cGy/5 fractions or 1325cGy/25 fractions as a simulatenous integrated boost. Participants randomized to the supine arm will be positioned supine on an angled breast board, with the ipsilateral arm abducted over her head. Participants randomized to the prone arm will be positioned prone on a prone breast board with both arms immobilized above the participant's head. The us of a cushion-like VaclocTM device is permitted at the treating physician's discretion. Radiation beams will be shaped to encompass the breast volume requiring treatment in both arms.
Study: NCT03944824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Plan using resistance bands
Description: Exercise under the guidance of an exercise physiologist using elastic resistance bands and weekly meeting with an exercise physiologist for 12 weeks
Study: NCT01064687

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2189265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT04002349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)
Description: Detailed in arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)
Description: Detailed in arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)
Description: Detailed in arm descriptions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% natural saline
Description: Detailed in arm descriptions
Study: NCT01064687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT01475214

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: potassium bicarbonate
Description: potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive placebo capsule
Description: microcrystalline cellulose
Study: NCT01741610

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cristalloid and colloid coloading
Description: Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cristalloid and colloid coloading
Description: Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cristalloid and colloid coloading
Description: Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
Study: NCT02961348

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early start of NOAC
Description: Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late start of NOAC
Description: Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
Study: NCT02764931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten free oats and gastrointestinal health
Description: Subjects will be served 3 different test meals in a randomized order in the cross-over design

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten free oats and gastrointestinal health
Description: Subjects will be served 3 different test meals in a randomized order in the cross-over design

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gluten free oats and gastrointestinal health
Description: Subjects will be served 3 different test meals in a randomized order in the cross-over design
Study: NCT02297295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy three times a week for 8 weeks according to a well-defined protocol
Study: NCT01064687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Study: NCT02356887

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Jugular venous ultrasound
Description: All volunteers will be fully awake throughout the study and be kept comfortable. A cross will be marked where the left and right IJV cross the level of C6. This is where all the measurements will be taken in 3 different conditions at rest, jugular occlusion and valsalva maneuver. At each conditions, the left and right IJV will be scanned with an ultrasound measuring the cross sectional area and Doppler velocity of the IJV. The least amount of pressure will be used to press on the ultrasound probe and the measurements will be obtained at end inspiration. The IJV flow is then calculated.
Study: NCT01490294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist,Gadovist, BAY86-4875)
Description: 0.01 mmol/kg BW (0.01 mL/kg) for stress MRI and 0.01 mmol/kg BW (0.01 mL/kg) for rest MRI (total dose 0.02 mmol/kg)
Study: NCT04144088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wu Ling San
Description: assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yin-Chen Wu Ling San
Description: assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.
Study: NCT01595867

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose (100 mg) placebo tablets crushed; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMBEDA - morphine sulfate/ naltrexone hydrochloride
Description: EMBEDA (morphine sulfate/naltrexone hydrochloride) 30 mg/ 1.2 mg extended release; capsule contents crushed; single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine sulfate CR crushed.
Description: Morphine sulfate controlled release 30 mg tablet crushed
Study: NCT04338451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music during the first part of ESWL
Description: Music listening during first part of ESWL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music during the second part of ESWL
Description: Music listening during second part of ESWL
Study: NCT02673866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a
Study: NCT03884868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iconographies to communicate risks
Description: Use of iconographies to communicate the risks of the different possible diagnosis after a positive FIT during the screening program nurse visit.
Study: NCT03356301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Non injected cardiac MRI exam
Study: NCT01490294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist,Gadovist, BAY86-4875)
Description: 0.025 mmol/kg BW (0.025 mL/kg) for stress MRI and 0.025 mmol/kg BW (0.025 mL/kg) for rest MRI (total dose 0.05 mmol/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist,Gadovist, BAY86-4875)
Description: 0.05 mmol/kg BW (0.05 mL/kg) for stress MRI and 0.05 mmol/kg BW (0.05 mL/kg) for rest MRI (total dose 0.1 mmol/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist,Gadovist, BAY86-4875)
Description: 0.1 mmol/kg BW (0.1 mL/kg) for stress MRI and 0.1 mmol/kg BW (0.1 mL/kg) for rest MRI (total dose 0.2 mmol/kg)
Study: NCT02673866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: pregabalin
Study: NCT02048215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
Study: NCT03356301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Non injected cardiac MRI exam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Applanation tonometry
Description: Applanation tonometry and ECG
Study: NCT02048215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet
Description: Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypocaloric diet
Description: Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
Study: NCT05571956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group
Description: Pancreatic masses were sampled using a 22-gauge FNB needle. If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs
Study: NCT03445390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 1 g intravenous given at the beginning and end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 1 g intravenous given at the beginning and end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match acetaminophen given at the beginning and end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match acetaminophen given at the beginning and end of surgery.
Study: NCT03381027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baby Massage
Description: Structured massage of the baby
Study: NCT01451190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured dermal and epidermal cells
Description: A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
Study: NCT02800590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-700
Study: NCT00865085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram HBr 40 mg tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study: NCT03938272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxabact OC5 - Oxalobacter formigenes Strain HC-1
Description: Live, commensal bacteria
Study: NCT02538094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial direct current stimulation
Description: Delivery of sham stimulation for 30 minutes using Neuro-Conn Direct Current (DC) Stimulator Plus.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct current stimulation
Description: Delivery of sham stimulation for 30 minutes using Neuro-Conn Direct Current (DC) Stimulator Plus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal Transcranial direct current stimulation
Description: Delivery of transcranial direct current stimulation for 30 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Anodal Transcranial direct current stimulation
Description: Delivery of transcranial direct current stimulation for 30 minutes.
Study: NCT01331174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed short wave
Description: The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pulsed short wave
Description: The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W.
Study: NCT04730726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSOT Acuity Echo
Description: Hybrid optoacoustic and ultrasonography imaging
Study: NCT03356301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Applanation tonometry
Description: Applanation tonometry and ECG
Study: NCT00865085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CelexaTM 40 mg tablets, single dose
Description: B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
Study: NCT01815632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early infusion of autologous marrow
Description: Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
Study: NCT03944824

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Modified Fried Frailty Scale
Description: Patients will be screened for frailty pre and post with sit-to-stand test, timed up and go test, handgrip strength test and administered the low physical activity questionnaire. These components together consist of the Modified Fried Frailty Index.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Modified Fried Frailty Scale
Description: Patients will be screened for frailty pre and post with sit-to-stand test, timed up and go test, handgrip strength test and administered the low physical activity questionnaire. These components together consist of the Modified Fried Frailty Index.
Study: NCT02072603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HITSystem
Description: Online, automated program designed to overcome current EID barriers by providing efficient prospective tracking of HIV-exposed infants and triggering electronic action alerts for both EID providers and lab technicians when time sensitive interventions are overdue for specific infants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: current procedures that follow Kenyan National EID guidelines to diagnose and manage HIV infection among HIV-exposed infants.
Study: NCT03957850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal Training
Description: The training procedure is adapted from a study by Denny \& Ochsner (2014). Before the task, participants are instructed that they will be presented pictures and that these pictures will be preceded by a condition specific cue signaling the appropriate strategy during picture viewing. Participants are instructed to indicate their affective response to the image on a rating scale. The task involves 4 conditions: 1) Negative-decrease: participants are asked to view negative pictures and to decrease their affective response by reappraising the negative event. 2) Negative-attend/ 3) Neutral-attend/ 4) Positive-attend: participants are asked to view pictures and to respond naturally to them without trying to alter their affective response. The training task will be repeated over 4 training sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Training
Description: The task in the control group is implemented to account for unspecific effects and is as similar as possible to the CR task except that it involves no negative-decrease (i.e., no reappraisal) condition. Instead, the control task only involves the three attend conditions (negative- attend, neutral-attend, positive-attend).
Study: NCT03417635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided focused attention
Description: Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The focused attention practice itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic music
Description: Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The acoustic music track itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.